Oncology-based in vivo CRO Market

Oncology-based in vivo CRO Market Overview

As per MRFR analysis, the Oncology-based in vivo CRO Market Size was estimated at 1.40 (USD Billion) in 2024. The Oncology-based in vivo CRO Market Industry is expected to grow from 1.51 (USD Billion) in 2025 to 3.10 (USD Billion) till 2034, at a CAGR (growth rate) is expected to be around 8.30% during the forecast period (2025 - 2034). Advancement in clinical procedures, growing discovery of medications and novel therapy techniques are the key market drivers accelerating market expansion.

Source: Primary Research, Secondary Research, MRFR Database and Analyst Review

Oncology-based in vivo CRO Market Trends

• Increasing cancer incidences are driving the market growth

Market CAGR for oncology-based in vivo CRO is being driven by the increase in the incidence of cancer. The study of cancer diagnosis, prevention, and therapy is known as oncology. In-vivo refers to within a living organism, and CRO stands for contract research organization. The management of cancer with the aid of contract research organization services is known as oncology-based in-vivo CRO.

Additionally, one of the key factors anticipated accelerating the growth and demand of the oncology-based in-vivo contract research organization (CRO) market is the increase in the prevalence of cancer around the world, a disease for which electrosurgical methods are appropriate. Additionally predicted during the forecast period of 2021 to 2028 is the straightforward availability of government funding for research and the rise in CROs' competence in treating cancer would both contribute to the expansion of the market. Additionally, a boost in the focus on oncogene research and an increase in genetic engineering discoveries are both anticipated to support market expansion.

In-vivo contract research organizations (CRO) based on oncology are expected to see significant growth opportunities within the anticipated window due to the rise in specific cancer treatments, the ease of access to a large percentage of medicines, and the rise in the use of these organizations for developing new cancer diagnoses and treatments. On the other hand, the high cost of clinical trials and strict regulatory approvals can impede the growth of the oncology-based in-vivo contract study organization (CRO) market. Additionally, the high cost of cancer drugs and their negative side effects are anticipated to restrain the development of the oncology-based in-vivo contract research organization (CRO) market.

As an illustration, the World Health Organization projects that there will be 19.3 million additional instances of cancer worldwide in 2020, contributing to an estimated 10 million deaths. Due to this, businesses are outsourcing basic research tasks in order to boost efficiency and concentrate on important development areas. Thus, result in driving the oncology-based in vivo CRO market revenue.

Oncology-based in vivo CRO Market Segment Insights

Oncology-based in vivo CRO Indication Insights

The oncology-based in vivo CRO market segmentation, based on Indication includes Blood cancer, Solid tumors, and Others. The solid tumors segment dominated the market. The motivation behind more research in the field of solid tumors is the existence of over 800 new drugs in the research pipeline being conducted by major pharmaceutical companies. Additionally, grants from organizations like the NIH and NCI are accessible, and the treatment gap for solid cancer continues to be one of the industry's most promising development drivers.

Oncology-based in vivo CRO Model Insights                             

The oncology-based in vivo CRO market segmentation, based on Model, includes Syngeneic model and Xenograft. The syngeneic model category generated the most income. Tumors created by murine cancer cells grafted onto genetically similar mouse strains are known as syngeneic mouse models. They are frequently employed as instruments for researching immunotherapy response and tumor immunity in the context of a fully developed murine immune system.

Figure 1:  Oncology-based in vivo CRO Market, by Model, 2022 & 2032 (USD Billion)

Source: Primary Research, Secondary Research, MRFR Database and Analyst Review

Oncology-based in vivo CRO Regional Insights

By region, the study provides the market insights into North America, Europe, Asia-Pacific and Rest of the World. The North American oncology-based in vivo CRO market area will dominate this market. This can be ascribed to the high level of technological development among the CROs in this area. A federal organization called the National Institutes of Health (NIH) provides funding and grants to assist research initiatives. The highest per-capita healthcare spending is in the United States.

Further, the major countries studied in the market report are the US, German, France, the UK, Canada, Italy, Spain, India, Australia, South Korea, China, Japan, and Brazil.

Figure 2:  ONCOLOGY-BASED IN VIVO CRO MARKET SHARE BY REGION 2022 (USD Billion)

Source: Primary Research, Secondary Research, MRFR Database and Analyst Review

Europe oncology-based in vivo CRO market takes second place in terms of market share due to the rise in R&D efforts and the requirement to cut back on overall trial expenses. Further, the German oncology-based in vivo CRO market held a dominant market share, and the UK oncology-based in vivo CRO market was the European region's fastest-growing market.

The Asia-Pacific Oncology-based in vivo CRO Market is anticipated to see the fastest CAGR between 2025 and 2034. This is due to untapped potential, a large patient base, economic growth, and a healthcare system that is constantly improving. Moreover, China’s oncology-based in vivo CRO market held a dominant market share, and the Indian oncology-based in vivo CRO market was the Asia-Pacific region's fastest-growing market.

Oncology-based in vivo CRO Key Market Players & Competitive Insights

Leading market players are putting a lot of money on R&D to increase the number of products they offer, which will fuel the growth of the oncology-based in vivo CRO industry. Additionally, market participants are engaging in a range of strategic initiatives to increase their worldwide reach, with important market developments such as the introduction of new products, contracts, mergers and acquisitions, increased investments, and cooperation with other businesses. To grow and endure in an increasingly competitive and challenging market environment, oncology-based in vivo CRO industry must provide reasonably priced goods.

One of the main business strategies employed by manufacturers is to produce locally to reduce operational expenses in the oncology-based in vivo CRO industry to develop market sector and provide benefits to customers. In recent years, the oncology-based in vivo CRO industry has provided some of the most important benefits for medicine. Major players in the oncology-based in vivo CRO market, including Biosciences, Charles River Laboratory (CRL), Covance, Crown Bioscience, Eurofins Scientific, ICON Plc, Taconic, and others, invest in operations for research and development in an effort to improve market demand.

Charles River Laboratories International, Inc. is a pharmaceutical firm based in the United States that offers a range of clinical and preclinical laboratory, gene therapy, and cell therapy services to the pharmaceutical, medical device, and biotechnology sectors. Additionally, it provides assistance with basic research, drug discovery, safety and efficacy, clinical support, production, and a range of biomedical products, outsourcing services, and animal research and development (for example, contract research organization services). Approximately 85% of unique FDA-approved medications in 2021, according to the business, were developed with support from them. In 2019, The company announced that it would pay EUR 448 million (USD 500 million) in cash to acquire Citoxlab, together with the previous purchases of the French firm AccelLAB, Atlanbio, and Solvo Biotechnology.

Labcorp Drug Development is an agreement-based research organization (CRO) that offers nonclinical, preclinical, clinical, and commercialization services to the pharmaceutical and biotechnology sectors. The organization was once known as Covance and is a part of Labcorp, which has over 70,000 employees ly. The world's largest central laboratory network, according to Labcorp Drug Development, is available. Animal rights activists, such as Jane Goodall, have fought Labcorp Drug Development vehemently over their use of animals in testing. In 2019, Covance and Envigo came to an agreement for Covance to purchase the nonclinical research services division of Envigo. Envigo acquired the research products division of Covance.

Key companies in the oncology-based in vivo CRO market include

• Biosciences
• Charles River Laboratory (CRL)
• Covance
• Crown Bioscience
• Eurofins Scientific
• ICON Plc
• Taconic
• The Jackson Laboratory
• Toxikon Inc.
• WuXi AppTec

Oncology-based in vivo CRO Industry Developments

April 2019: Charles River said that it would stop operating in San Diego and transfer the job to one of its facilities in Northern California. Additionally, the business maintains locations in California's South San Francisco and Hollister. The breeding of mice used by scientists to test substances, which was done in San Diego, was relocated to Hollister, California.

October 2021: The 3D ex Vivo Patient Tissue Platform was introduced by Crown Bioscience. The platform utilizes the patient's tumor tissue, which is removed by biopsies, surgical resections, ascites, or from samples of pleural effusion and processed to retain the tumor microenvironment.

April 2021: Evotec SE made a financial investment in OxVax, an immune-oncology startup based on research from Oxford University that paves the way for the development of cancer vaccines that could outperform that now in use. The vaccine from OxVax will teach the body's defenses to recognize and destroy cancers.

Oncology-based in vivo CRO Market Segmentation

Oncology-based in vivo CRO Indication Outlook

• Blood cancer
• Solid tumors
• Others

Oncology-based in vivo CRO Model Outlook

• Syngeneic model
• Xenograft

Oncology-based in vivo CRO Regional Outlook

• US
• Canada

• Germany
• France
• UK
• Italy
• Spain
• Rest of Europe

• China
• Japan
• India
• Australia
• South Korea
• Australia
• Rest of Asia-Pacific

• Middle East
• Africa
• Latin America

Oncology-based in Vivo CRO Market Segmentation

Oncology-based in Vivo CRO Indication Outlook (USD Billion, 2018-2032)

• Blood cancer
• Solid tumors
• Others

Oncology-based in Vivo CRO Model Outlook (USD Billion, 2018-2032)

• Syngeneic model
• Xenograft

Oncology-based in Vivo CRO Regional Outlook (USD Billion, 2018-2032)

• North America Outlook (USD Billion, 2018-2032)
  • North America Oncology-based in Vivo CRO by Indication
    • Blood cancer
    • Solid tumors
    • Others
  • North America Oncology-based in Vivo CRO by Model
    • Syngeneic model
    • Xenograft
  • US Outlook (USD Billion, 2018-2032)
  • US Oncology-based in Vivo CRO by Indication
    • Blood cancer
    • Solid tumors
    • Others
  • US Oncology-based in Vivo CRO by Model
    • Syngeneic model
    • Xenograft
  • CANADA Outlook (USD Billion, 2018-2032)
  • CANADA Oncology-based in Vivo CRO by Indication
    • Blood cancer
    • Solid tumors
    • Others
  • CANADA Oncology-based in Vivo CRO by Model
    • Syngeneic model
    • Xenograft
  • Europe Outlook (USD Billion, 2018-2032)
    • Europe Oncology-based in Vivo CRO by Indication
      • Blood cancer
      • Solid tumors
      • Others
    • Europe Oncology-based in Vivo CRO by Model
      • Syngeneic model
      • Xenograft
    • Germany Outlook (USD Billion, 2018-2032)
    • Germany Oncology-based in Vivo CRO by Indication
      • Blood cancer
      • Solid tumors
      • Others
    • Germany Oncology-based in Vivo CRO by Model
      • Syngeneic model
      • Xenograft
    • France Outlook (USD Billion, 2018-2032)
    • France Oncology-based in Vivo CRO by Indication
      • Blood cancer
      • Solid tumors
      • Others
    • France Oncology-based in Vivo CRO by Model
      • Syngeneic model
      • Xenograft
    • UK Outlook (USD Billion, 2018-2032)
    • UK Oncology-based in Vivo CRO by Indication
      • Blood cancer
      • Solid tumors
      • Others
    • UK Oncology-based in Vivo CRO by Model
      • Syngeneic model
      • Xenograft
    • ITALY Outlook (USD Billion, 2018-2032)
    • ITALY Oncology-based in Vivo CRO by Indication
      • Blood cancer
      • Solid tumors
      • Others
    • ITALY Oncology-based in Vivo CRO by Model
      • Syngeneic model
      • Xenograft
    • SPAIN Outlook (USD Billion, 2018-2032)
    • Spain Oncology-based in Vivo CRO by Indication
      • Blood cancer
      • Solid tumors
      • Others
    • Spain Oncology-based in Vivo CRO by Model
      • Syngeneic model
      • Xenograft
    • Rest Of Europe Outlook (USD Billion, 2018-2032)
    • Rest Of Europe Oncology-based in Vivo CRO by Indication
      • Blood cancer
      • Solid tumors
      • Others
    • REST OF EUROPE Oncology-based in Vivo CRO by Model
      • Syngeneic model
      • Xenograft
    • Asia-Pacific Outlook (USD Billion, 2018-2032)
      • Asia-Pacific Oncology-based in Vivo CRO by Indication
        • Blood cancer
        • Solid tumors
        • Others
      • Asia-Pacific Oncology-based in Vivo CRO by Model
        • Syngeneic model
        • Xenograft
      • ChinaOutlook (USD Billion, 2018-2032)
      • China Oncology-based in Vivo CRO by Indication
        • Blood cancer
        • Solid tumors
        • Others
      • China Oncology-based in Vivo CRO by Model
        • Syngeneic model
        • Xenograft
      • Japan Outlook (USD Billion, 2018-2032)
      • Japan Oncology-based in Vivo CRO by Indication
        • Blood cancer
        • Solid tumors
        • Others
      • Japan Oncology-based in Vivo CRO by Model
        • Syngeneic model
        • Xenograft
      • India Outlook (USD Billion, 2018-2032)
      • India Oncology-based in Vivo CRO by Indication
        • Blood cancer
        • Solid tumors
        • Others
      • India Oncology-based in Vivo CRO by Model
        • Syngeneic model
        • Xenograft
      • AustraliaOutlook (USD Billion, 2018-2032)
      • Australia Oncology-based in Vivo CRO by Indication
        • Blood cancer
        • Solid tumors
        • Others
      • Australia Oncology-based in Vivo CRO by Model
        • Syngeneic model
        • Xenograft
      • Rest of Asia-Pacific Outlook (USD Billion, 2018-2032)
      • Rest of Asia-Pacific Oncology-based in Vivo CRO by Indication
        • Blood cancer
        • Solid tumors
        • Others
      • Rest of Asia-Pacific Oncology-based in Vivo CRO by Model
        • Syngeneic model
        • Xenograft
      • Rest of the World Outlook (USD Billion, 2018-2032)
        • Rest of the World Oncology-based in Vivo CRO by Indication
          • Blood cancer
          • Solid tumors
          • Others
        • Rest of the World Oncology-based in Vivo CRO by Model
          • Syngeneic model
          • Xenograft
        • Middle EastOutlook (USD Billion, 2018-2032)
        • Middle East Oncology-based in Vivo CRO by Indication
          • Blood cancer
          • Solid tumors
          • Others
        • Middle East Oncology-based in Vivo CRO by Model
          • Syngeneic model
          • Xenograft
        • Africa Outlook (USD Billion, 2018-2032)
        • Africa Oncology-based in Vivo CRO by Indication
          • Blood cancer
          • Solid tumors
          • Others
        • Africa Oncology-based in Vivo CRO by Model
          • Syngeneic model
          • Xenograft
        • Latin America Outlook (USD Billion, 2018-2032)
        • Latin America Oncology-based in Vivo CRO by Indication
          • Blood cancer
          • Solid tumors
          • Others
        • Latin America Oncology-based in Vivo CRO by Model
          • Syngeneic model
          • Xenograft